Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.

@article{Anand2011PrognosticVO,
  title={Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.},
  author={Inder S. Anand and Thomas S. Rector and John G. F. Cleland and Michael A. Kuskowski and Robert McKelvie and Hans Persson and John J V McMurray and Michael R. Zile and Michel Komajda and Barry M. Massie and Peter E. Carson},
  journal={Circulation. Heart failure},
  year={2011},
  volume={4 5},
  pages={569-77}
}
BACKGROUND Plasma concentrations of natriuretic peptides (NPs) are associated with morbidity and mortality in patients with systolic heart failure (HF). However, the role of NP as a prognostic marker in patients with HF and preserved ejection fraction (HFpEF) has not been studied in a large cohort of well-characterized patients. Moreover, it is unclear whether treatments have a differential effect on morbidity and mortality across the spectrum of NP levels. METHODS AND RESULTS N-terminal pro… CONTINUE READING